Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...

Namibia has made significant strides in stemming the spread of HIV and AIDS through education and prevention. However, for people like Anna Engomba, the arrival of new, life-saving medication cannot ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

[2] Measures of effectiveness include pregnancy rate per treatment cycle, cumulative clinical pregnancy rate (CCPR) and cumulative live-birth rate (CLBR), while rates of HIV seroconversion and ...

In the 1990s, many people considered a HIV diagnosis a death sentence because of the limited available treatment options. While the numbers of people with HIV remains high, treatment and ...